Theravance initiates TD-4208 Phase 2b dose ranging study
06:12 EST 12 Dec 2012 | Pharmaceutical Business Review
Theravance has commenced Phase 2b study desined to evaluate varying doses of TD-4208 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Original Article: Theravance initiates TD-4208 Phase 2b dose ranging study
More From BioPortfolio on "Theravance initiates TD-4208 Phase 2b dose ranging study"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
